California-based Erasca announced Thursday it is expanding its existing partnership with Pfizer to assess ERAS-007 in combination with Pfizer’s Ibrance (palbociclib).
https://www.pharmalive.com/wp-content/uploads/2021/10/Pfizer-and-Voyager-Launch-630-Million-Gene-Therapy-Technology-Pact-BioSpace-10-6-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-20 17:21:112022-10-21 10:27:34Pfizer and Erasca target pancreatic, colorectal cancer with "synergistic" pairing
